Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences is expected to continue its positive momentum with the development of its innovative ABC platform, which has shown promising results in its investigational medicines. The recent positive topline results from the Phase 3 GLOW2 trial for tarcocimab tedromer in diabetic retinopathy, combined with the prior successful trials for tarcocimab in other retinal diseases, support our thesis that the ABC platform can provide extended dosing regimens and improved efficacy without significant safety concerns. With an increased probability of success for tarcocimab tedromer and KSI-501, we see a potential for strong commercial revenues in the future. However, like any developmental-stage biopharmaceutical company, there are risks to consider, such as the failure to secure capital resources and potential setbacks in program development and commercialization. Looking ahead, we are anticipating further positive results from ongoing trials and are particularly interested in seeing readthrough from the early clinical data for KSI-101 to the pivotal trial profile for KSI-501.

Bears say

Kodiak Sciences is facing potential setbacks with their ABC platform and investigational medicines, specifically with failures in clinical trials for DME and wet AMD. With upcoming Phase 3 data for tarcocimab in DR, there is potential for validation of the reformulated design, but the overall efficacy profile for the ABC platform is still uncertain and may hinder their success in the retinal therapy market. Overall, there are significant questions surrounding Kodiak's capabilities and their ability to differentiate themselves, making their stock an unappealing investment at this time.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.